UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Amendment No.___)

Under the Securities Exchange Act of 1934

Eyegate Pharmaceuticals, Inc. (Name of Issuer)

COMMON STOCK, \$0.01 PER SHARE PAR VALUE

(Title of Class of Securities)

30233M 107 (CUSIP Number)

February 19, 2015

(Date of Event Which Requires Filing of this Statement)

☐ Rule 13d-1(b)			
☐ Rule 13d-1(c)			
☑ Rule 13d-1(d)			
wm : 1	1 11 1 (211 1	 .1	 c

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 30233M 107

1	NAMES OF REPORTING PERSON		
	NPE Coinvest 1	NPE Coinvest 1	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □ (b) □		
3	SEC USE ONLY		
4	CITIZENSHIP OR PL	ACE OF ORGA	NIZATION
	France		
		5	SOLE VOTING POWER
	NUMBER OF SHARES		737,647*
	BENEFICIALLY	6	SHARED VOTING POWER
	OWNED BY		0
	EACH REPORTING	7	SOLE DISPOSITIVE POWER
PERSON 727 647*		737.647*	
	WITH:	8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	737.647*		
10			
11	1 DEDOCENT OF CLASS DEDDESCRITED BY AMOUNT IN DOW O		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	11.5%**		
12	TYPE OF REPORTING PERSON		
	00		

Includes 63,442 shares of the Issuer's common stock ("Common Stock") issuable upon exercise of warrants beneficially owned by the Reporting Person.

The percentage was calculated based on 6,328,604 shares of Common Stock issued and outstanding as reported by the Issuer in its Prospectus (the "Prospectus") filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 13, 2015.

CUSIP No. 30233M 107

1	NAMES OF REPORTING PERSON		
	Natixis Private Equity	Natixis Private Equity	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b) (a)		
3	SEC USE ONLY		
4	CITIZENSHIP OR PI	CITIZENSHIP OR PLACE OF ORGANIZATION	
	France		
		5	SOLE VOTING POWER
	NUMBER OF 737,647*		737,647*
	SHARES BENEFICIALLY	6	SHARED VOTING POWER
	OWNED BY 0		0
	EACH REPORTING 7 SOLE DISPOSITIVE POWER		SOLE DISPOSITIVE POWER
	PERSON 737,647*		
	WIIH:	8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT	BENEFICIALL	Y OWNED BY EACH REPORTING PERSON
	737.647*		
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES "		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	11.5%** TYPE OF REPORTING PERSON		
	00		

Includes 63,442 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Person.

The percentage was calculated based on 6,328,604 shares of Common Stock issued and outstanding as reported by the Issuer in the Prospectus.

CUSIP No. 30233M 107

1	NAMES OF REPORTING PERSON			
	Dominique Sabassier			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □ (b) □			
3	SEC USE ONLY			
4	CITIZENSHIP OR PL	ACE OF ORGA	INIZATION	
	France			
		5	SOLE VOTING POWER	
NUMBER OF 737,647*		1.2.7.		
	SHARES BENEFICIALLY	6	SHARED VOTING POWER	
	OWNED BY		0	
EACH 7		7	SOLE DISPOSITIVE POWER	
PERSON 727.647*		737.647*		
	WITH:	8	SHARED DISPOSITIVE POWER	
			0	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	737.647*			
10	<i>'</i>			
4.4				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	11.5%**			
12	TYPE OF REPORTING PERSON			
	IN			

Includes 63,442 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Person.
 The percentage was calculated based on 6,328,604 shares of Common Stock issued and outstanding as reported by the Issuer in the Prospectus.

ITEM 1.

- (a) Name of Issuer. Eyegate Pharmaceuticals, Inc., a Delaware Corporation (the "Issuer")
- (b) Address of Issuer's Principal Executive Offices 271 Waverley Oaks Road, Suite 108, Waltham, MA 02452.

ITEM 2.

- (a) Name of Persons Filing
 - i. NPE Coinvest 1 ("NPEC")
 - ii. Natixis Private Equity, by virtue of its ownership of NPEC ("NPE")
 - iii. Dominique Sabassier, President and General Manager of NPEC and General Manager of NPE, with voting and investment power with respect to the foregoing entities

The persons named in this Item 2(a) are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."

- (b) Address of Principal Business Office or, if none, Residence of all Reporting Persons 5 7, rue de Monttessuy, 75340 Paris cedex 07, France
- (c) Citizenship of all Reporting Persons: France
- (d) Title of class of securities: Common Stock

Not applicable.

(e) - CUSIP No.: 30233M 107

ITEM 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (a) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (b) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (c) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. (d) 80a-8). An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (e) (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. (h) (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

ITEM 4. Ownership

(a) Amount beneficially owned:

(j) 🗆

(k) □

i. NPEC - 737,647*

- ii. NPE 737,647*
- iii. Dominique Sabassier 737,647*

(b) Percent of class:

i. NPEC 11.5%**

ii. NPE 11.5%**

iii. Dominique Sabassier

11.5%**

- Number of shares as to which the person
 - (i) Sole power to vote or to direct the vote:
 - i. NPEC 737,647* ii. NPE -
 - 737,647* iii. Dominique Sabassier 737,647*
 - (ii) Shared power to vote to direct the

vote:

(c)

- i. NPEC -None
- ii. NPE -
- iii. Dominique Sabassier None
- (iii) Sole power to dispose or to direct the disposition

of: i. NPEC -737,647* ii. NPE -737,647*

iii. Dominique Sabassier 737,647*

(iv) Shared power to dispose or to direct the disposition

of:

- i. NPEC -None
- ii. NPE -None
- iii. Dominique Sabassier
- * Includes 63,442 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Person.
- ** The percentage was calculated based on 6,328,604 shares of Common Stock issued and outstanding as reported by the Issuer in the Prospectus.

Each Reporting Person disclaims beneficial ownership other than those shares of Common Stock which such Reporting Person owns of record.

ITEM 5. Ownership of Five Percent or Less of a Class

Not applicable.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

ITEM 6. Ownership of More than Five Percent on behalf of Another Person

Not applicable.

ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

ITEM 8. Identification and Classification of Members of the Group

Not applicable.

ITEM 9. Notice of Dissolution of Group

Not applicable.

ITEM 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Date: March 4, 2015
NATIXIS PRIVATE EQUITY
By: /s/ Dominique Sabassier
Dominique Sabassier, General Manager
NPE COINVEST 1
By: /s/ Dominique Sabassier
Dominique Sabassier, President and General Manager
/s/ Dominique Sabassier
Dominique Sabassier

AGREEMENT OF JOINT FILING

This undersigned hereby agree, pursuant to Rule 13d-1(k)(1) under the Securites Exchange Act of 1934, as amended (the "Act"), that a statement of beneficial ownership as required under Sections 13(g) or 13(d) of the Act and the Rules promulgated thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings.

Date: March 2, 2015	
NATIXIS PRIVATE EQUITY	
By: /s/ Dominique Sabassier Dominique Sabassier, General Manager	_
NPE COINVEST 1	
By: /s/ Dominique Sabassier Dominique Sabassier, President and General Manager	-
/s/ Dominique Sabassier Dominique Sabassier	_